Review of Oral Oncology and Supportive Care

Needs Statement

Hematologist-oncologists, radiation oncologists, surgeons, other medical specialists, basic and translational research scientists, residents, fellows, and medical students need to be regularly updated on advances in the diagnosis and management of patients with hematologic disorders and related malignancies. The series aims to broaden the knowledge base of learners in these topic areas and improve their competencies to enhance the patient care experience and outcomes.

Educational Objectives

At the conclusion of the session, the participants should be able to:

• Compare the anticancer mechanisms of action of oral tyrosine kinase inhibitors (TKIs) and describe how their differences affect their toxicity profiles.
• Recommend appropriate monitoring parameters for currently approved TKIs and recognize areas of ambiguity.
• Design agent-specific approaches to manage TKI toxicities.

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Approval

June 1, 2021 through June 30, 2023. Original release date: June 1, 2021

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.